At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 110 enrolled
Drug / intervention
Raloxifene +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center, Randomized, Double-blind, Double-dummy Study in Postmenopausal Women With Low Bone Mineral Density to Compare the Effects of a Single Dose of i.v. Zoledronic Acid 5 mg, With Daily Oral Raloxifene 60 mg OD on Bone Turnover Markers
In Brief
A Phase 4 clinical trial evaluating Raloxifene, Zoledronic acid, and 2 other interventions for Osteoporosis. Completed, enrolled 110 participants across 17 sites.
Detailed Summary
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedFeb 2007
Primary CompletionJul 2008
TodayJul 2026
First PostedFeb 5, 2007
Enrollment StartJan 1, 2007
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 19.4 years ago
Interventions
Raloxifenedrug
Zoledronic aciddrug
Placebo oral pillsdrug
Placebo intravenous (i.v.) infusiondrug